Russia has developed a new crown vaccine for nasal drips

Maksutov, director of the "Vector" National Center for Virology and Biotechnology of the Russian Federation's Consumer Protection and Public Interest Supervision Agency, said the center had developed a nasal drip-in new coronavirus vaccine on May 21.Maksutov said the center has selected the three most promising of the six vaccines it has developed for clinical trials by the end of June. One of the vaccines, based on peptide antigens, not only has different functional origins, but also different immunization methods and programmes, not the usual intramyal injection, but the nasal drip-in dosing. The technical path of the vaccine was well validated when the Ebola virus vaccine was developed in 2018.Animal tests of the three vaccines showed no elevated body temperature and no adverse reactions observed in the animals after the vaccination. This shows that animals show good tolerance to vaccination. To monitor possible changes in the animal's lungs, the researchers also used X-ray machines to confirm, Maksutov said.The Russian National Science Center for Vector Virology and Biotechnology in Siberia is a leader in the development of a new coronavirus vaccine. Using methods such as recombinative protein vaccines and synthetic vaccines, the Centre has been working on vaccine development on six technical routes, including influenza, measles and blister oralitis viruses in the recombinative protein vaccine and synthetic vaccine technology routes, and six vaccines were tested in animals on 13 April.Previously, the Russian Ministry of Health,Gamarrea National Research Center for Epidemiology and Microbiology, in cooperation with the Russian Ministry of Defense, developed a vaccine for adenovirus vectors and tested all the staff at the center who developed the new coronavirus vaccine. Kinzburg, the center's director, said tests showed the vaccine was performing well and had produced protective antibodies. But he said the move should not be seen as a test of the vaccine, which is self-protection to continue working.WHO has included in the alternative list the results of research on nine new coronavirus vaccines developed in Russia, six from the National Science Centre for Vector Virology and Biotechnology, two from the Russian biopharmaceutical company Bioad and one from the St. Petersburg Institute for Vaccines and Serum Research. (Science and Technology Daily)